<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00532675</url>
  </required_header>
  <id_info>
    <org_study_id>CLBH589B2206</org_study_id>
    <secondary_id>2006-007030-35</secondary_id>
    <nct_id>NCT00532675</nct_id>
  </id_info>
  <brief_title>Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.</brief_title>
  <official_title>A Phase Ib, Multi-center, Open-label, Dose-escalation Study of Oral LBH589 When Administered in Combination With Oral Lenalidomide &amp; Dexamethasone in Adult Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety of LBH589 given in combination with lenalidomide and
      dexamethasone in adult patients with multiple myeloma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 22, 2008</start_date>
  <completion_date type="Actual">November 8, 2017</completion_date>
  <primary_completion_date type="Actual">November 8, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the highest and safest dose of LBH589 when it is administered in combination with lenalidomide &amp; dexamethasone</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessed by monitoring of adverse events, serious adverse events and laboratory parameters To characterize the pharmacokinetic profile of the study treatment To characterize the pharmacodynamic profile of the study treatment</measure>
    <time_frame>Da1 to Day 3 (week 1 of first cycle)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>PAN 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panobinostat 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAN 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panobinostat 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAN 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panobinostat 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAN 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panobinostat 25 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LBH589</intervention_name>
    <description>PAN 5 mg and PAN 20 mg capsules</description>
    <arm_group_label>PAN 10 mg</arm_group_label>
    <arm_group_label>PAN 20 mg</arm_group_label>
    <arm_group_label>PAN 25 mg</arm_group_label>
    <arm_group_label>PAN 5 mg</arm_group_label>
    <other_name>Panobinostat, PAN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide 5mg or 25 mg</description>
    <arm_group_label>PAN 10 mg</arm_group_label>
    <arm_group_label>PAN 20 mg</arm_group_label>
    <arm_group_label>PAN 25 mg</arm_group_label>
    <arm_group_label>PAN 5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients must have a diagnosis of active multiple myeloma

          -  Patients must have received at least one prior line of therapy and their disease has
             relapsed..

          -  Patients must be suitable for treatment with lenalidomide &amp; dexamethasone.

          -  Adults ≥ 18 years old

          -  ECOG Performance Status ≤ 2

          -  Life expectancy &gt; 12 weeks

          -  Patients must have acceptable neutrophil and platelet counts as well as adequate
             kidney and liver function.

          -  Able to sign informed consent and to comply with the protocol

        Exclusion criteria:

          -  Primary refractory MM

          -  Peripheral neuropathy ≥ CTCAE grade 2

          -  Impaired cardiac function or clinically significant cardiac diseases

          -  Impairment of GI function or GI disease that may significantly alter the absorption of
             LBH589

          -  Patients with diarrhea &gt; CTCAE grade 1

          -  Patients using medications that have a relative risk of prolonging the QT interval

          -  Concomitant use of CYP3A4 inhibitors

          -  Patients with a history of deep vein thrombosis or thromboembolism within &lt; 6 months
             prior to starting study treatment

          -  Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or
             who have not recovered from side effects of such therapy

          -  Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)
             not using 2 reliable forms of birth control

          -  Male patients whose sexual partners are WOCBP and who are unable to use a latex condom
             during sexual contact (even if they have undergone a vasectomy)

          -  Patients with any significant history of non-compliance to medical regimens or
             unwilling or unable to comply with the instructions given to him/her by the study
             staff.

        Other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla Y Leon</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 18, 2007</study_first_submitted>
  <study_first_submitted_qc>September 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2007</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloma</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Revlimid</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>LBH589</keyword>
  <keyword>Combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

